MA56526B1 - Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine - Google Patents

Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine

Info

Publication number
MA56526B1
MA56526B1 MA56526A MA56526A MA56526B1 MA 56526 B1 MA56526 B1 MA 56526B1 MA 56526 A MA56526 A MA 56526A MA 56526 A MA56526 A MA 56526A MA 56526 B1 MA56526 B1 MA 56526B1
Authority
MA
Morocco
Prior art keywords
immunodeficiency virus
human immunodeficiency
pyrido
inhibitors
virus replication
Prior art date
Application number
MA56526A
Other languages
English (en)
Other versions
MA56526A (fr
Inventor
Eric P Gillis
Christiana Iwuagwu
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of MA56526A publication Critical patent/MA56526A/fr
Publication of MA56526B1 publication Critical patent/MA56526B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un composé et ses sels pharmaceutiquement acceptables, ainsi que des compositions et des méthodes de traitement d'une infection par le virus de l'immunodéficience humaine (vih).
MA56526A 2019-06-19 2020-06-17 Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine MA56526B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962863406P 2019-06-19 2019-06-19
PCT/IB2020/055653 WO2020254985A1 (fr) 2019-06-19 2020-06-17 Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine

Publications (2)

Publication Number Publication Date
MA56526A MA56526A (fr) 2022-04-27
MA56526B1 true MA56526B1 (fr) 2024-05-31

Family

ID=71738195

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56526A MA56526B1 (fr) 2019-06-19 2020-06-17 Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine

Country Status (34)

Country Link
US (2) US12129255B2 (fr)
EP (1) EP3986561B1 (fr)
JP (1) JP7628512B2 (fr)
KR (1) KR102932817B1 (fr)
CN (2) CN119039288A (fr)
AR (1) AR119174A1 (fr)
AU (1) AU2020295793B2 (fr)
BR (1) BR112021025655A2 (fr)
CA (1) CA3143136A1 (fr)
CL (1) CL2021003388A1 (fr)
CO (1) CO2021017479A2 (fr)
CR (1) CR20210664A (fr)
DK (1) DK3986561T3 (fr)
ES (1) ES2974541T3 (fr)
FI (1) FI3986561T3 (fr)
HR (1) HRP20240501T1 (fr)
HU (1) HUE065762T2 (fr)
IL (1) IL288750B2 (fr)
LT (1) LT3986561T (fr)
MA (1) MA56526B1 (fr)
MD (1) MD3986561T2 (fr)
MX (1) MX2021016149A (fr)
MY (1) MY206712A (fr)
PE (1) PE20220510A1 (fr)
PH (1) PH12021553180A1 (fr)
PL (1) PL3986561T3 (fr)
PT (1) PT3986561T (fr)
RS (1) RS65304B1 (fr)
SI (1) SI3986561T1 (fr)
SM (1) SMT202400153T1 (fr)
TW (1) TWI850403B (fr)
UA (1) UA128967C2 (fr)
UY (1) UY38755A (fr)
WO (1) WO2020254985A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020084492A1 (fr) 2018-10-24 2020-04-30 VIIV Healthcare UK (No.5) Limited Inhibiteurs de la réplication du virus de l'immunodéficience humaine
MX2021016149A (es) 2019-06-19 2022-05-18 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de inmunodeficiencia humana.
CA3138332A1 (fr) 2019-06-19 2020-12-24 Nmd Pharma A/S Composes destines au traitement de troubles neuromusculaires
EP4037661A1 (fr) * 2019-10-01 2022-08-10 VIIV Healthcare Company Procédé de traitement du vih à l'aide de cabotégravir et de rilpivirine
MX2022006940A (es) * 2019-12-09 2022-07-11 Viiv Healthcare Co Composiciones farmaceuticas.
IL296182A (en) * 2020-03-06 2022-11-01 Viiv Healthcare Uk No 5 Ltd Inhibitors of human immunodeficiency virus replication
MX2022012881A (es) * 2020-04-15 2022-11-08 Viiv Healthcare Uk No 5 Ltd Inhibidores de replicacion del virus de inmunodeficiencia humana.
US20240423985A1 (en) * 2021-10-13 2024-12-26 Viiv Healthcare Uk (No.5) Limit-Ed Inhibitors of human immunodeficiency virus replication
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於ｈｉｖ之治療性化合物
CN121335877A (zh) 2023-06-15 2026-01-13 Viiv保健英国第五有限公司 用于制备化合物的方法和中间体
WO2025169059A1 (fr) 2024-02-05 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibiteurs de la réplication du virus de l'immunodéficience humaine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52489B (sr) 2001-02-02 2013-02-28 Bristol-Myers Squibb Company Kompozicija i antivirusna aktivnost derivata supstituisanog azaindoloksoacetat piperazina
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
CN102143962B (zh) * 2008-07-02 2015-03-11 爱维艾珂瑟有限公司 具有抗病毒特性的化合物
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
JP6205354B2 (ja) 2011-07-06 2017-09-27 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のための化合物
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
WO2014110298A1 (fr) 2013-01-09 2014-07-17 Gilead Sciences, Inc. Hétéroaryles à 5 chaînons et leur utilisation comme agents antiviraux
PT2943493T (pt) 2013-01-09 2017-10-23 Gilead Sciences Inc Compostos terapêuticos para o tratamento de infecções virais
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130964A1 (fr) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Composés thérapeutiques
WO2015130966A1 (fr) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Agents antiviraux
JP6491321B2 (ja) 2014-08-29 2019-03-27 ギリアード サイエンシーズ， インコーポレイテッド 抗レトロウイルス剤
DK3347352T3 (da) * 2016-08-19 2019-08-26 Gilead Sciences Inc Terapeutiske forbindelser anvendelige til profylaktisk eller terapeutisk behandling af en hiv-virusinfektion
US10640499B2 (en) * 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
WO2020084492A1 (fr) * 2018-10-24 2020-04-30 VIIV Healthcare UK (No.5) Limited Inhibiteurs de la réplication du virus de l'immunodéficience humaine
UY38559A (es) * 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
MX2021016149A (es) 2019-06-19 2022-05-18 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de inmunodeficiencia humana.

Also Published As

Publication number Publication date
DK3986561T3 (da) 2024-03-04
KR102932817B1 (ko) 2026-03-04
PH12021553180A1 (en) 2022-11-07
FI3986561T3 (fi) 2024-05-02
UY38755A (es) 2020-11-30
CL2021003388A1 (es) 2022-09-30
EP3986561B1 (fr) 2024-02-14
MA56526A (fr) 2022-04-27
US12129255B2 (en) 2024-10-29
KR20220024608A (ko) 2022-03-03
UA128967C2 (uk) 2024-12-11
HRP20240501T1 (hr) 2024-07-05
BR112021025655A2 (pt) 2022-02-01
SI3986561T1 (sl) 2024-04-30
TW202115055A (zh) 2021-04-16
US20210323967A1 (en) 2021-10-21
MD3986561T2 (ro) 2024-06-30
AR119174A1 (es) 2021-12-01
JP2022537047A (ja) 2022-08-23
PL3986561T3 (pl) 2024-06-10
EP3986561A1 (fr) 2022-04-27
IL288750A (en) 2022-02-01
ES2974541T3 (es) 2024-06-27
LT3986561T (lt) 2024-04-25
MY206712A (en) 2025-01-03
HUE065762T2 (hu) 2024-06-28
US20250019383A1 (en) 2025-01-16
IL288750B2 (en) 2025-04-01
AU2020295793B2 (en) 2023-07-06
CO2021017479A2 (es) 2022-04-19
CN114245795B (zh) 2024-08-06
MX2021016149A (es) 2022-05-18
TWI850403B (zh) 2024-08-01
CN114245795A (zh) 2022-03-25
JP7628512B2 (ja) 2025-02-10
PT3986561T (pt) 2024-03-15
CA3143136A1 (fr) 2020-12-24
CN119039288A (zh) 2024-11-29
SMT202400153T1 (it) 2024-05-14
RS65304B1 (sr) 2024-04-30
WO2020254985A1 (fr) 2020-12-24
AU2020295793A1 (en) 2022-01-20
CR20210664A (es) 2022-01-21
IL288750B1 (en) 2024-12-01
PE20220510A1 (es) 2022-04-07

Similar Documents

Publication Publication Date Title
MA56526B1 (fr) Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
PH12021550813A1 (en) Inhibitors of human immunodeficiency virus replication
SA522432955B1 (ar) Kras g12c مثبطات
CR20240147A (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t
MA44721B1 (fr) Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
UY38559A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
EA202192433A1 (ru) Соединения, полезные в терапии вич
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
MA35109B1 (fr) Derives de nucleoside 2-substitues et procedes d'utilisation de ceux-ci pour le traitement de maladies virales
MA42811B1 (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MX2020011317A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih.
MA63589B1 (fr) Dérivés d'alpha-d-galactopyranoside substitués par triazolyl-méthyle
MX2022011016A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana.
WO2021232067A8 (fr) Inhibition de stats3 pour le traitement et la prévention d'une infection à coronavirus humain
UY27577A1 (es) Inhibidores de la integrasa del vih
MA43960A (fr) Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1
MX2022012881A (es) Inhibidores de replicacion del virus de inmunodeficiencia humana.
MX2025013861A (es) Compuestos anti virus de la inmunodeficiencia humana (vih)
JOP20240119A1 (ar) مشتقات نافثيريدينون لمعالجة مرض أو اضطراب
ZA202204251B (en) Compounds and compositions for the treatment of parasitic diseases
MY201070A (en) Novel triterpene derivatives as hiv inhibitors
CL2024003598A1 (es) Derivados de piperazina y uso en la terapia contra el vih.
MA43507B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MX2025010182A (es) Métodos para el tratamiento de las infecciones por gripe